HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk ReductionPR Newswire·Jul 14 at 03:30 AMBIOA-63.62%688222-4.24%
HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor | BIOA Stock NewsStockTitan·Sep 15, 2025 at 08:30 AM688222-4.24%
HitGen: Partner BioAge launches Phase I clinical study of novel NLRP3 inhibitor BGE-102Zhitong·Sep 14, 2025 at 08:12 PM688222-4.24%
A-share innovative drug concept stocks fluctuated lower, with InventisBio falling over 10%. Other stocks such as Huahai Pharmaceutical, JENKEM, Lifeon Pharmaceutical, JOINN, Guangsheng Tang, HitGen, and Baillie Gifford also dropped more than 6%Zhitong·Sep 9, 2025 at 01:19 AM688356-3.91%603127-1.18%
Innovative drug concept stocks are repeatedly active, Chimin hits the daily limitZhitong·Sep 3, 2025 at 08:41 PM688356-3.91%688658-0.73%
A-share innovative drug concept stocks rose again, with Chemexpress, HitGen, and Medicilon increasing by over 10%, while Bide and WuXi AppTec also followed suitWallstreetcn·Aug 29, 2025 at 12:12 AM688222-4.24%688202-5.93%
09:30 ET Advancing DEL Technology for the Research Lab: HitGen Introduces OpenDEL™ 5.0prnewswire·Aug 27, 2025 at 08:31 AM688222-4.24%
The three major A-share indices closed mixed at midday, with the CRO concept leading the decline36Kr·Aug 6, 2025 at 10:36 PM002463-2.06%300476-0.58%
HitGen: Shareholders plan to reduce their holdings by no more than 5 million shares of the companyZhitong·Aug 4, 2025 at 05:10 AM688222-4.24%
Innovative drug concept stocks are repeatedly active, HitGen and CHENGDA PHARMA both rise over 10%Zhitong·Jul 21, 2025 at 08:52 PM688222-4.24%301201+1.69%
